OrbiMed’s Nektar Therapeutics NKTR Stock Holding History

OrbiMed’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-34,333	Closed	-$296K	–	137
2023 Q2	$296K	Sell	34,333 -2,000	-6%	-$21.3K	0.01%	126
2023 Q1	$383K	Buy	+36,333	New	+$1.1M	0.01%	123

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's NKTR Position: Q2 2026 in Review

OrbiMed increased its Nektar Therapeutics (NKTR) stake by 69% in Q2 2026, buying an estimated $13.9M and bringing the position to 465,346 shares worth $32.5M. The position accounts for 0.6% of the portfolio, ranked #48.

OrbiMed first reported a position in NKTR in Q1 2023 and has held it in 3 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

OrbiMed held 465,346 shares of Nektar Therapeutics worth $32.5M as of Q2 2026.
OrbiMed bought 190,346 Nektar Therapeutics shares in Q2 2026, an estimated $13.9M.
Nektar Therapeutics made up 0.6% of OrbiMed's portfolio in Q2 2026, its #48 holding.
OrbiMed first reported a position in Nektar Therapeutics in Q1 2023 and has held it in 3 quarters since.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.